BridgeMD
New treatment option for AML
Official title UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
ClinicalTrials.gov ID: NCT06047886
What this study is testing
What is Infusion of CD34 selected hematopoietic stem cells?
Infusion of CD34 selected hematopoietic stem cells is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for aml.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell boost or an additional hematopoietic stem cell transplantation procedure. In such settings standard immune suppression strategies are avoided due to their myelosuppressive nature.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 4 to 75
You may be able to join if
- AML in morphologic remission with intermediate/high-risk features or relapsed disease 1 or 2
- ALL in morphologic remission with high-risk features or relapsed disease 1 or 2
- Lymphoid malignancies in CR or PR (e.g. non-Hodgkin's lymphoma, prolymphocytic leukemia, CLL)
- Myelodysplastic syndromes with \<=10% blasts
- CML in morphologic remission after blast phase or accelerated phase
You likely can't join if
- Non-compliant patients.
- No appropriate caregivers identified.
- Uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (Discretion of the attending physician).
- Patients with known allergy to DMSO.
- Pregnant or breastfeeding women
See the full eligibility criteria
- AML in morphologic remission with intermediate/high-risk features or relapsed disease 1 or 2
- ALL in morphologic remission with high-risk features or relapsed disease 1 or 2
- Lymphoid malignancies in CR or PR (e.g. non-Hodgkin's lymphoma, prolymphocytic leukemia, CLL)
- Myelodysplastic syndromes with \<=10% blasts
- CML in morphologic remission after blast phase or accelerated phase
- Primary myelofibrosis with \<=10% blasts \^morphologic remission is defined as \<5% blasts on the bone marrow biopsy. Negative test for donor-specific antibody within 28 days of starting conditioning regimen, or...
- Non-compliant patients.
- No appropriate caregivers identified.
- Uncontrolled medical or psychiatric disorders which may preclude patients to undergo clinical studies (Discretion of the attending physician).
- Patients with known allergy to DMSO.
- Pregnant or breastfeeding women
The study team makes the final eligibility decision.
Where it's taking place
- Birmingham, Alabama, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 4 weeks to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Birmingham, Alabama, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.